Purificação e incorporação de C-FICOCIANINA em sistemas de liberação para avaliação da atividade cicatrizante

Abstract

The increase in socio-environmental changes has encouraged the search for ecologically friendly inputs in the global industry. In this context, phycobiliproteins from microalgae have become an asset of great interest to the pharmaceutical, cosmetic, and food industries due to their diverse biological activities, color/fluorescence, non-toxicity, and origin from renewable sources. This work aims to demonstrate the value of this protein for pharmaceutical purposes, as it is applied to healing, as well as the development of a release system capable of maintaining the molecule's stability in aqueous media. To this end, a patent search for C-FC related to different drug delivery systems provided a basic overview of the market and future projections. In addition, delivery systems were developed to incorporate C-FC for healing use. Patent prospecting has shown that technological maturity concerning the topic is growing, and the presence of medicines on the market with bioactivity is not yet observed; the reasonable market projections encourage investment in research and development in this area. In addition, it was observed that C-FC can be incorporated into different delivery systems, with its therapeutic application being more predominant in anticancer drugs. In the development of the release systems, it was possible to observe that liposomes were not able to encapsulate the active ingredient due to the method used to make the system, but Synperonic® 127 and Carbopol® 996 gels were able to incorporate C-FC, the former being able to promote greater stability to the active ingredient. The results indicate that the formulation obtained may have woundhealing potential.